■ Cardio-oncology: an overview on outpatient management and future developments
- J. Teske, M. Linschoten, J. A. M. Kamphuis et al
Neth Heart J. 2018 Nov; 26(11): 521–532.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220023/
■ Cardio-oncology: a new sub-specialty
J Bennett, A R Lyon, C Plummer et al
The British Journal of Cardiology jan 2018
https://bjcardio.co.uk/2018/01/cardio-oncology-a-new-sub-specialty/
■ Terapia Antiplaquetária em Pacientes com Câncer de Mama em Uso de Terapia Hormonal: Mitos, Evidências e Potencialidades – Revisão Sistemátic
Leite, Andréa de Melo et al
Arq. Bras. Cardiol., Aug 2018, vol.111, no.2, p.205-212
■ Mechanism and management of cancer chemotherapy-induced atherosclerosis
Mikio Mukai, Keiko Komori, Toru Oka
J Atheroscler Thromb. 2018 Oct 1; 25(10): 994–1002
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193189/
■ Cardiotoxicity of anticancer therapeutics
J Dong, H Chen
Front Cardiovasc Med 2018, vol 5: 9
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810267/
■ Fadiga: Um Sintoma Complexo e seu Impacto no Câncer e na Insuficiência Cardíaca
Borges, Jacqueline Aparecida et al.
Int. J. Cardiovasc. Sci., Aug 2018, vol.31, no.4, p.433-442
■ Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice: an opinion paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiograph
Hyungseop Kim, Woo-Baek Chung, Kyoung Im Cho et al
J Cardiovasc Ultrasound. 2018 Mar; 26(1): 1–25
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881080/
■ Modern-day cardio-oncology: a report from the ´Heart Failure and World Congress on Acute Heart Failure 2018
Markus S. Anker, Alessia Lena, Sara Hadzibegovic et al
for the Heart Failure Association Cardio‐Oncology Study Group of the European Society of Cardiology
ESC Heart Fail. 2018 Dec; 5(6): 1083–1091
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300814/
■ Cardio-oncology: protecting the heart from curative breast cancer treatment
Jenica N. Upshaw
Gland Surg. 2018 Aug; 7(4): 350–365
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107590/
■ 5-fluorouracil and cardiotoxicity: a review
Jaskanwal D. Sara, Jasvinder Kaur, Ryan Khodadadi et al
Ther Adv Med Oncol. 2018; 10: 1758835918780140
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024329/
■ Biomarkers for the detection of apparent and subclinical cancer theraphy-related cardiotoxicity
Lars Michel, Tienush Rassaf, Matthias Totzeck
J Thorac Dis. 2018 Dec; 10(Suppl 35): S4282–S4295
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328390/
■ Cardiovascular and cancer risk: the role of cardio-oncology
Jessica Shank Coviello
J Adv Pract Oncol. 2018 Mar; 9(2): 160–176
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303003/
■ Role of biomarkers in prediction of cardiotoxicity during câncer treatment
Li-Ling Tan, Alexander R. Lyon
Curr Treat Options Cardiovasc Med. 2018; 20(7): 55.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008350/
■ Cardiotoxicidade Decorrente do Tratamento com Doxorrubicina e Exercício Físico: Revisão Sistemática
Maia, Tauan Nunes et al.
Int. J. Cardiovasc. Sci., Feb 2017, vol.30, no.1, p.70-80
■ Cardiotoxicidade na terapêutica com antraciclinas: estratégias de prevenção
M Cruz, J Duarte-Rodrigues, M Campelo
Revista Portuguesa de Cardiologia junho 2016
■ by Dr Paulo Fernando Leite
Cardiologia – Centro Médico Unimed BH
Rua Gonçalves Dias 202
Belo Horizonte/MG/Brasil
tel 40204020
CRMMG: 7026
Email: pfleite1873@gmail.com